It will compete in haemophilia A with Roche’s hugely successful Hemlibra (emicizumab), which has less frequent dosing, is approved for patients with and without inhibitors, and is approaching $5 ...

T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer. HealthDay News — For patients with human epidermal growth factor receptor ...